It is estimated that 32 to 35 million adults in the United States experience an episode of major depressive disorder during their lifetime. When depressed patients present to their healthcare provider for treatment, outcomes are often less than satisfactory. For patients who, despite treatment, continue to suffer from depression, a modest 22%-30% will achieve remission.
Treatment resistance depression can have a severe impact on patient quality of life, and in certain circumstances, may lead to suicide. As well as the burden on time and other resources spent recognizing and diagnosing its etiology, outcomes for those patients with TRD who are not appropriately treated or referred may be adversely affected. Successful recognition, diagnosis, and management of depression is associated with better patient outcomes, and ultimately in savings of both clinic time and resources.
References
Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
Beesdo K, Bittner A, Pine DS, et al. Incidence of social anxiety disorder and consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry. 2007;64:903-912.
Demitrack M. Therapeutic neuromodulation - the arrival of a paradigm shift. Presented at the American Psychiatric Association 159th Annual Meeting; May 20-25, 2006; Toronto, Ontario, Canada. Abstract 39A.
Presented by The Johns Hopkins University School of Medicine in collaboration with the Depression and Bipolar Support Alliance, and
developed through a strategic educational facilitation with MJ Consulting Group.
Supported by an educational grant from Eli Lilly and Co. and Bristol-Myers Squibb, Inc.